May‐Thurner syndrome and thrombosis: A systematic review of antithrombotic use after endovascular stent placement
Author(s): ,
Leslie J. Padrnos
Division of Hematology, Mayo Clinic Arizona, Phoenix
Correspondence|Leslie J. Padrnos, Division of Hematology, Mayo Clinic Arizona, Phoenix, AZ 85054.|Email:
David Garcia
Division of Hematology, University of Washington, Seattle
ISTH Academy. Padrnos L.
Jan 15, 2019; 273423
Dr. Leslie Padrnos
Dr. Leslie Padrnos
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

Click here to join ISTH or renew your membership.

You may also access ISTH content "anytime, anywhere" with the FREE ISTH Academy App for iOS and Android.
Journal Abstract
Discussion Forum (0)
Rate & Comment (0)
May‐Thurner Syndrome (MTS) is caused by compression of the left common iliac vein between the right common iliac artery and the pelvis. It likely predisposes an individual to lower extremity deep vein thrombosis (DVT) as well as symptoms of unilateral lower extremity swelling and discomfort in the absence of a known history of thrombosis. In the case of MTS‐associated acute thrombosis, there is low‐quality evidence to suggest that endovascular intervention including thrombolysis and endovascular stent placement reduces the risk of recurrent thrombosis. However, the optimal type and duration of antithrombotic therapy after stent placement for left iliofemoral vein stenosis is not known.
A systematic literature search including studies that evaluated the outcome of endovascular stent occlusion and systemic anticoagulant use in patients with MTS associated DVT was performed. The primary outcome of interest was 12‐month risk of endovascular stent occlusion or recurrent DVT.
A total of five studies encompassing 61 patients were included in our study. All studies were retrospective without a comparator group. A variety of anticoagulants and durations were prescribed. Of the 55 patients evaluable, the 12‐month rate of endovascular stent occlusion or recurrent DVT ranged from 0% to 40%. The 12‐month stent patency rate ranged from 60% to 100%.
The published evidence regarding antithrombotic treatment for patients with MTS who have undergone stent placement for a DVT is limited. Further high‐quality, prospective studies are needed in this setting to inform clinical decision making.
antithrombotic, deep vein thrombosis, endovascular stent, iliac venous compression syndrome, May‐Thurner syndrome, stent occlusion
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings